Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...

Following an initial report from Reuters, Merck KGaA confirmed that it is in talks with SpringWorks for a potential ...

Merck’s 2025 guidance fell short of Wall Street expectations. - Spencer Platt/Getty Images Investors have taken to punishing pharma companies that appear unable to gauge demand for their top ...

Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical ...

Merck stock has shown some solid short-term strength, with its stock price of $98.90 comfortably sitting above its eight-day and 20-day simple moving averages (SMAs) of $97.81 and $98.64 ...

SpringWorks Therapeutics ( NASDAQ: SWTX) soared ~40% after a report that Merck KGaA ( OTCPK:MKGAF) is in advanced discussions ...

Earnings are painting a mixed picture within the pharmaceutical space Tuesday morning, as Merck (MRK) and Pfizer (PFE) reported their fourth quarter results.

Aims to revolutionize pharmaceutical manufacturing with focus on advanced aseptic processing technology.

About aimed analytics aimed analytics, a pioneering company in AI-based data analytics, is enabling innovation in pharmaceutical ... collaboration with MSD/Merck for its Phase 2 study, OPTIMUS ...

The stock currently trades near its 52-week low of $94.48, potentially presenting an opportunity as InvestingPro's Fair Value analysis ... Merck operates in a highly competitive pharmaceutical ...